Charles River Laboratories International (NYSE:CRL) Given New $180.00 Price Target at Evercore ISI

Charles River Laboratories International (NYSE:CRL - Get Free Report) had its price objective raised by analysts at Evercore ISI from $170.00 to $180.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an "outperform" rating on the medical research company's stock. Evercore ISI's target price suggests a potential upside of 10.00% from the stock's previous close.

CRL has been the topic of a number of other research reports. The Goldman Sachs Group cut shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $190.00 to $170.00 in a report on Friday, March 21st. Robert W. Baird raised their price objective on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a report on Thursday, May 8th. TD Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price on the stock in a report on Wednesday, May 14th. Wall Street Zen cut shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a report on Saturday, July 5th. Finally, Mizuho cut their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $174.54.

Charles River Laboratories International Stock Up 2.9%

Charles River Laboratories International stock traded up $4.66 during trading on Wednesday, reaching $163.63. The stock had a trading volume of 828,706 shares, compared to its average volume of 1,031,763. The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.78. Charles River Laboratories International has a 52-week low of $91.86 and a 52-week high of $254.15. The business has a 50 day moving average price of $144.04 and a 200 day moving average price of $152.01. The stock has a market cap of $8.04 billion, a PE ratio of -251.74, a P/E/G ratio of 5.38 and a beta of 1.49.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The company had revenue of $984.17 million for the quarter, compared to analysts' expectations of $942.34 million. During the same quarter last year, the company earned $2.27 earnings per share. The firm's revenue for the quarter was down 2.7% on a year-over-year basis. On average, analysts predict that Charles River Laboratories International will post 9.36 EPS for the current year.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president directly owned 19,513 shares of the company's stock, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.30% of the company's stock.

Hedge Funds Weigh In On Charles River Laboratories International

Several institutional investors have recently bought and sold shares of CRL. Rothschild Investment LLC increased its stake in Charles River Laboratories International by 480.0% in the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock valued at $26,000 after buying an additional 144 shares during the period. Brooklyn Investment Group grew its stake in shares of Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company's stock worth $27,000 after purchasing an additional 86 shares during the period. HM Payson & Co. acquired a new position in shares of Charles River Laboratories International during the 1st quarter worth $31,000. Optiver Holding B.V. acquired a new position in shares of Charles River Laboratories International during the 4th quarter worth $37,000. Finally, GeoWealth Management LLC grew its stake in shares of Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after purchasing an additional 190 shares during the period. 98.91% of the stock is owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).